These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 17006840)
1. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)]. Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241 [TBL] [Abstract][Full Text] [Related]
4. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Dam HQ; Kim SM; Lin HC; Intenzo CM Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323 [TBL] [Abstract][Full Text] [Related]
6. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy. Lind P; Gallowitsch HJ Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519 [TBL] [Abstract][Full Text] [Related]
7. Differentiated thyroid carcinoma: Incremental diagnostic value of Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475 [TBL] [Abstract][Full Text] [Related]
8. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi]. Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839 [TBL] [Abstract][Full Text] [Related]
9. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. Muratet JP; Daver A; Minier JF; Larra F J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340 [TBL] [Abstract][Full Text] [Related]
10. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328 [TBL] [Abstract][Full Text] [Related]
12. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course]. Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706 [TBL] [Abstract][Full Text] [Related]
14. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer. Gerard SK; Dam HQ Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947 [No Abstract] [Full Text] [Related]
15. Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact. Hsu CC; Chen YW; Huang YF; Chuang YW Nucl Med Commun; 2007 Sep; 28(9):681-7. PubMed ID: 17667746 [TBL] [Abstract][Full Text] [Related]
16. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617 [TBL] [Abstract][Full Text] [Related]
17. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565 [TBL] [Abstract][Full Text] [Related]
18. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788 [TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. Silberstein EB J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976 [TBL] [Abstract][Full Text] [Related]
20. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]